CAMA-1 is a luminal-type human breast cancer cell line that displays rounded morphology in adherent tissue culture. These cells are considered Her2-negative and estrogen-receptor/progesterone-receptor (ER/PR)-positive. They are responsive to estrogen and sensitive to growth inhibition by tamoxifen. The CAMA-1 cells have an in-frame mutation in the E-cadherin gene, resulting in a truncated, non-functional protein. In addition, they have oncogenic mutations in PTEN and p53 and amplification of the cyclin D1 gene.
This cell line was established in 1975 from the pleural effusion of a 51-year-old Caucasian female with malignant adenocarcinoma of the breast.
Jorgen Fogh, PhD, formerly at Sloan Kettering Institute, Memorial Sloan Kettering
- Fogh J et al. (1977) Absence of HeLa cell contamination in 169 cell lines derived from human tumors. Journal of the National Cancer Institute 58: 209-214 (PubMed ID: 833871)
- Ji H et al. (1994) Absence of transforming growth factor-beta responsiveness in the tamoxifen growth-inhibited human breast cancer cell line CAMA-1. Journal of Cellular Biochemistry 54: 332-342 (PubMed ID: 8200913)
- van Horssen R et al. (2012) E-cadherin promotor methylation and mutation are inversely related to motility capacity of breast cancer cells. Breast Cancer Research and Treatment 136: 365-377 (PubMed ID: 23053649)
This cell line may be licensed nonexclusively for research or commercial purposes.
For internal research purposes by a commercial entity: Utilize MSK’s Express License, available here. In order to streamline and expedite the licensing of select MSK cell lines, the terms of this non-exclusive license are non-negotiable. Please note: This license is only available for select cell lines, including this one.
To proceed, please download this contract, fill in all relevant fields, and email a scanned version to Alexandra Buga at email@example.com. Once this license has been executed by MSK, you will receive a signed copy and invoice, and can then place your order with ATCC.
For licensing requests for a commercial purpose: Contact Alexandra Buga, MS, MBA, Licensing Associate, Office of Technology Development, MSK, 646-888-1078, firstname.lastname@example.org.
For non-licensing requests from academic-research institutions: Contact Frances Weis-Garcia, PhD, Associate Laboratory Member/Head, Antibody & Bioresource Core Facility, MSK, 646-888-2354, email@example.com.